(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 April 2009 (02.04.2009)

PCT

(10) International Publication Number
WO 2009/040134 A1

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61K 33/24 (2006.01)

(21) International Application Number:
PCT/EP2008/008233

(22) International Filing Date:
26 September 2008 (26.09.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07018946.9 26 September 2007 (26.09.2007) EP
60/975,485 26 September 2007 (26.09.2007) US

(71) Applicants *(for all designated States except US)*: **U3 PHARMA AG** [DE/DE]; Bunsenstrasse 1, 82152 Martinsried (DE). **AMGEN INC.** [US/US]; One Center Drive, Thousand Oaks, CA 91320-1799 (US).

(71) Applicant *(for US only)*: **ZWICK-WALLASCH, Esther** [DE/DE]; Frühlingsstrasse 112, 82131 Gauting (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROTHE, Mike** [DE/DE]; Elisenstrasse 4, 82152 Krailing (DE). **PRENZEL, Norbert** [DE/DE]; Pentenriedderstr. 32, 82152 Krailing (DE). **BORGES, Eric** [DE/AT]; Roseggergasse 25, A-2344 Maria Enzersdorf (AT). **HETTMANN, Thore** [DE/DE]; Am Stadtpark 38D, 81243 München (DE).

(74) Agent: **WEICKMANN & WEICKMANN**; Postfach 860 820, 81635 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

[Continued on next page]

(54) Title: HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR ANTIGEN BINDING PROTEINS

Fig 38A



(57) Abstract: Provided herein are antigen binding proteins, e.g.,human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.

WO 2009/040134 A1

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*